{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:44:05Z","timestamp":1791834245460,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cystic fibrosis (CF) is the most common inherited disease in Caucasian populations, affecting around 50,000 patients in Europe and 30,000 in United States. A mutation in CF trans-membrane conductance regulator (<jats:italic>CFTR<\/jats:italic>) gene changes a protein (a regulated chloride channel), which is expressed in many tissues. Defective <jats:italic>CFTR<\/jats:italic> results in reduced chloride secretion and an overage absorption of sodium across the epithelia, leading to thickened secretions in organs such as pancreas and lung. Gradually, there have been considerable improvements in the survival of people with CF, thanks to substantial changes in specialized CF care and the discovery of new <jats:italic>CFTR<\/jats:italic> modulators drugs. Nevertheless, lung disease remains the most common cause of death. For these reasons improvement of sputum clearance is a major therapeutic aim in CF. So far, symptomatic mucolytic therapy is mainly based on inhalation of dornase alfa, hypertonic saline or mannitol, in combination with physiotherapy. The major component of mucus in CF is pus including viscous material such as polymerized DNA derived from degraded neutrophils. Dornase alfa cleaves the DNA released from the neutrophils and reduces mucous viscosity, and further prevent airway infections and damage to the lung parenchyma. In this review we will summarize the current knowledge on dornase alfa in the treatment of CF lung disease, especially highlighting the positive effect on lung clearance index, a sensitive measure of ventilation inhomogeneity.<\/jats:p>","DOI":"10.1186\/s13052-022-01331-5","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T09:04:10Z","timestamp":1659603850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index"],"prefix":"10.1186","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"1331_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8:65\u2013124.","journal-title":"Lancet Respir Med"},{"key":"1331_CR2","doi-asserted-by":"publisher","first-page":"L953","DOI":"10.1152\/ajplung.00545.2018","volume":"316","author":"AKM Shamsuddin","year":"2019","unstructured":"Shamsuddin AKM, Quinton PM. Concurrent absorption and secretion of airway surface liquids and bicarbonate secretion in human bronchioles. Am J Physiol Lung Cell Mol Physiol. 2019;316:L953\u201360.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1331_CR3","doi-asserted-by":"publisher","first-page":"113195","DOI":"10.1016\/j.ejmech.2021.113195","volume":"213","author":"E Bardin","year":"2021","unstructured":"Bardin E, Pastor A, Semeraro M, Golec A, Hayes K, Chevalier B, et al. Modulators of CFTR. Updates on clinical development and future directions. Eur J Med Chem. 2021;213:113195.","journal-title":"Eur J Med Chem"},{"key":"1331_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jcf.2014.01.007","volume":"13","author":"V Terlizzi","year":"2014","unstructured":"Terlizzi V, Tosco A, Tomaiuolo R, Sepe A, Amato N, Casale A, et al. Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis. J Cyst Fibros. 2014;13:579\u201384.","journal-title":"J Cyst Fibros"},{"key":"1331_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12890-018-0766-6","volume":"18","author":"V Terlizzi","year":"2018","unstructured":"Terlizzi V, Lucarelli M, Salvatore D, Angioni A, Bisogno A, Braggion C, et al. Clinical expression of cystic fibrosis in a large cohort of Italian siblings. BMC Pulm Med. 2018;18:196.","journal-title":"BMC Pulm Med"},{"key":"1331_CR6","first-page":"296","volume":"24","author":"FAL Marson","year":"2018","unstructured":"Marson FAL. Disease-modifying genetic factors in cystic fibrosis. CurrOpinPulm Med. 2018;24:296\u2013308.","journal-title":"CurrOpinPulm Med"},{"key":"1331_CR7","first-page":"38","volume":"24","author":"VM Sofia","year":"2018","unstructured":"Sofia VM, Surace C, Terlizzi V, Da Sacco L, Alghisi F, Angiolillo A, et al. Trans-heterozygosity for mutations enhances the risk of recurrent\/chronic pancreatitis in patients with Cystic Fibrosis. MolMed. 2018;24:38.","journal-title":"MolMed"},{"key":"1331_CR8","first-page":"669","volume":"65","author":"V Terlizzi","year":"2013","unstructured":"Terlizzi V, De Gregorio F, Sepe A, Amato N, Arduino C, Casale A, et al. Brand new SPINK1 and CFTR mutations in a child with acute recurrent pancreatitis: a case report. Minerva Pediatr. 2013;65:669\u201372.","journal-title":"Minerva Pediatr"},{"key":"1331_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jcf.2016.12.012","volume":"16","author":"J Barben","year":"2017","unstructured":"Barben J, Castellani C, Dankert-Roelse J, Gartner S, Kashirskaya N, Linnane B, et al. The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. J Cyst Fibros. 2017;16:207\u201313.","journal-title":"J Cyst Fibros"},{"key":"1331_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/diagnostics10070446","volume":"10","author":"G Taccetti","year":"2020","unstructured":"Taccetti G, Botti M, Terlizzi V, Cavicchi MC, Neri AS, Galici V, et al. Clinical and genotypical features of false-negative patients in 26 years of Cystic Fibrosis neonatal screening in Tuscany, Italy. Diagnostics (Basel). 2020;10:446.","journal-title":"Diagnostics (Basel)"},{"key":"1331_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-2600(16)00053-9","volume":"4","author":"C Castellani","year":"2016","unstructured":"Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med. 2016;4:653\u201361.","journal-title":"Lancet Respir Med"},{"key":"1331_CR12","doi-asserted-by":"publisher","first-page":"F448","DOI":"10.1136\/fn.88.6.F448","volume":"88","author":"M Super","year":"2003","unstructured":"Super M. Cystic fibrosis newborn screening and detection of carriers. Arch Dis Child Fetal Neonatal Ed. 2003;88:F448\u20139.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1331_CR13","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jpeds.2016.09.066","volume":"181S","author":"CL Ren","year":"2017","unstructured":"Ren CL, Borowitz DS, Gonska T, Howenstine MS, Levy H, Massie J, et al. Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and Cystic Fibrosis screen positive, inconclusive diagnosis. J Pediatr. 2017;181S:S45\u2013511.","journal-title":"J Pediatr"},{"issue":"20","key":"1331_CR14","first-page":"30909","volume":"S1569\u20131993","author":"J Barben","year":"2020","unstructured":"Barben J, Castellani C, Munck A, Davies JC, de Winter-de Groot KM, Gartner S, et al. Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator related metabolic syndrome\/cystic fibrosis screen positive, inconclusive diagnosis (CRMS\/CFSPID). J Cyst Fibros. 2020;S1569\u20131993(20):30909\u201317.","journal-title":"J Cyst Fibros"},{"key":"1331_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jcf.2021.03.015","volume":"20","author":"V Terlizzi","year":"2021","unstructured":"Terlizzi V, Claut L, Tosco A, Colombo C, Raia V, Fabrizzi B, et al. A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS\/CFSPID) in six Italian centres. J Cyst Fibros. 2021;20:828\u201334.","journal-title":"J Cyst Fibros"},{"key":"1331_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jpeds.2007.03.002","volume":"151","author":"VA LeGrys","year":"2007","unstructured":"LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ Jr, Cystic Fibrosis Foundation. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr. 2007;151:85\u20139.","journal-title":"J Pediatr"},{"key":"1331_CR17","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","volume":"181S","author":"PM Farrell","year":"2017","unstructured":"Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, et al. Diagnosis of Cystic Fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181S:S4-S15.e1.","journal-title":"J Pediatr"},{"issue":"Suppl 2","key":"1331_CR18","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/S1569-1993(11)60014-3","volume":"10","author":"C Bombieri","year":"2011","unstructured":"Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011;10(Suppl 2):S86-102.","journal-title":"J Cyst Fibros"},{"key":"1331_CR19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a single Phe508del Allele. N Engl J Med. 2019;381:1809\u201319.","journal-title":"N Engl J Med"},{"key":"1331_CR20","doi-asserted-by":"publisher","first-page":"106646","DOI":"10.1016\/j.rmed.2021.106646","volume":"189","author":"V Carnovale","year":"2021","unstructured":"Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Medio P, Ferrillo L, et al. Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype. Respir Med. 2021;189:106646.","journal-title":"Respir Med"},{"key":"1331_CR21","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/jcm11051283","volume":"11","author":"B Cabral","year":"2022","unstructured":"Cabral B, Terlizzi V, Laselva O, Conte Filho C, Mota F. Anticipating new treatments for Cystic Fibrosis: a global survey of researchers. J Clin Med. 2022;11:1283.","journal-title":"J Clin Med"},{"key":"1331_CR22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/17460441.2020.1750592","volume":"15","author":"L Guerra","year":"2020","unstructured":"Guerra L, Favia M, Di Gioia S, Laselva O, Bisogno A, Casavola V, et al. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. Expert Opin Drug Discov. 2020;15:873\u201391.","journal-title":"Expert Opin Drug Discov"},{"key":"1331_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00063030-200519030-00001","volume":"19","author":"R Suri","year":"2005","unstructured":"Suri R. The use of human deoxyribonuclease (rhDNAse) in the management of cystic fibrosis. BioDrugs. 2005;19:135\u201344.","journal-title":"BioDrugs"},{"key":"1331_CR24","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1378\/chest.128.4.2327","volume":"128","author":"TE Robinson","year":"2005","unstructured":"Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, Moss RB. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest. 2005;128:2327\u201335.","journal-title":"Chest"},{"key":"1331_CR25","first-page":"CD001127","volume":"9","author":"C Yang","year":"2018","unstructured":"Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018;9:CD001127.","journal-title":"Cochrane Database Syst Rev"},{"key":"1331_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jama.1968.03140310070022","volume":"205","author":"J Lieberman","year":"1968","unstructured":"Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA. 1968;205:312\u20133.","journal-title":"JAMA"},{"key":"1331_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17:153\u201378.","journal-title":"J Cyst Fibros"},{"key":"1331_CR28","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","volume":"187","author":"PJ Mogayzel Jr","year":"2013","unstructured":"Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1331_CR29","unstructured":"Cystic Fibrosis Foundation Patient Registry Annual Data Report 2020.  https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"1331_CR30","unstructured":"European Cystic Fibrosis Society Patient Registry Annual Data Report 2019. https:\/\/www.ecfs.eu\/sites\/default\/files\/general-content-images\/working-groups\/ecfs-patient-registry\/ECFSPR_Report_2019_v1_23Dec2021.pdf."},{"key":"1331_CR31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJM199409083311003","volume":"331","author":"HJ Fuchs","year":"1994","unstructured":"Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331:637\u201342.","journal-title":"N Engl J Med"},{"key":"1331_CR32","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","volume":"358","author":"R Suri","year":"2001","unstructured":"Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison ofhypertonic saline and alternate-day or daily recombinant human deoxyribonucleasein children with cystic fibrosis: a randomised trial. Lancet. 2001;358:1316\u201321.","journal-title":"Lancet"},{"key":"1331_CR33","first-page":"CD007923","volume":"3","author":"R Dentice","year":"2021","unstructured":"Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev. 2021;3:CD007923.","journal-title":"Cochrane Database Syst Rev"},{"key":"1331_CR34","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1378\/chest.110.4.889","volume":"110","author":"K McCoy","year":"1996","unstructured":"McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease Pulmozyme Study Group. Chest. 1996;110:889\u201395.","journal-title":"Chest"},{"key":"1331_CR35","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1080\/08035250600752466","volume":"95","author":"B Frederiksen","year":"2006","unstructured":"Frederiksen B, Pressler T, Hansen A, Koch C, H\u00f8iby N. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr. 2006;95:1070\u20134.","journal-title":"Acta Paediatr"},{"key":"1331_CR36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1067\/mpd.2001.118570","volume":"139","author":"JM Quan","year":"2001","unstructured":"Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001;139:813\u201320.","journal-title":"J Pediatr"},{"key":"1331_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1164\/rccm.200307-959OC","volume":"169","author":"K Paul","year":"2004","unstructured":"Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, et al. Bronchoalveolar lavage for the evaluation of antiinflammatory treatment study group. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med. 2004;169:719\u201325.","journal-title":"Am J Respir Crit Care Med"},{"key":"1331_CR38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jcf.2018.08.004","volume":"18","author":"SJ Newsome","year":"2019","unstructured":"Newsome SJ, Daniel RM, Carr SB, Bilton D, Keogh RH. Investigating the effects of long-term dornase alfa use on lung function using registry data. J Cyst Fibros. 2019;18:110\u20137.","journal-title":"J Cyst Fibros"},{"key":"1331_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/thx.2009.116970","volume":"65","author":"C Minasian","year":"2010","unstructured":"Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, dailyrhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax. 2010;65:51\u20136.","journal-title":"Thorax"},{"key":"1331_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/ppul.25740","volume":"57","author":"D AdemhanTural","year":"2022","unstructured":"AdemhanTural D, Yal\u00e7\u0131n E, Emiralioglu N, Ozsezen B, Sunman B, NayirBuyuksahin H, et al. Comparison of inhaled mannitol\/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis. Pediatr Pulmonol. 2022;57:142\u201351.","journal-title":"Pediatr Pulmonol"},{"key":"1331_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13052-021-01117-1","volume":"47","author":"V Terlizzi","year":"2021","unstructured":"Terlizzi V, Masi E, Francalanci M, Taccetti G, Innocenti D. Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice. Ital J Pediatr. 2021;47:168.","journal-title":"Ital J Pediatr"},{"key":"1331_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jcf.2014.02.005","volume":"13","author":"JG Mainz","year":"2014","unstructured":"Mainz JG, Schien C, Schiller I, Sch\u00e4dlich K, Koitschev A, Koitschev C, et al. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst Fibros. 2014;13:461\u201370.","journal-title":"J Cyst Fibros"},{"key":"1331_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00405-021-06875-6","volume":"279","author":"J Krajewska","year":"2022","unstructured":"Krajewska J, Zub K, S\u0142owikowski A, Zato\u0144ski T. Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options. Eur Arch Otorhinolaryngol. 2022;279:1\u201324.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1331_CR44","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/archotol.131.12.1097","volume":"131","author":"M Cimmino","year":"2005","unstructured":"Cimmino M, Nardone M, Cavaliere M, Plantulli A, Sepe A, Esposito V, et al. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease. Arch Otolaryngol Neck Surg. 2005;131:1097.","journal-title":"Arch Otolaryngol Neck Surg"},{"key":"1331_CR45","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/alr.22082","volume":"8","author":"GB Shah","year":"2018","unstructured":"Shah GB, De Keyzer L, Russell JA, Halderman A. Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review. Int Forum Allergy Rhinol. 2018;8:729\u201336.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1331_CR46","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jcf.2020.08.004","volume":"20","author":"EF McKone","year":"2021","unstructured":"McKone EF, Jackson AD, Fletcher G, Kirwan L. Dornase alfa and rate of lung function decline in European patients with cystic fibrosis: a retrospective registry cohort study. J Cyst Fibros. 2021;20:552\u20134.","journal-title":"J Cyst Fibros"},{"key":"1331_CR47","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1164\/rccm.201309-1634ST","volume":"188","author":"MA Spruit","year":"2013","unstructured":"Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society\/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J RespirCrit Care Med. 2013;188:e13-64.","journal-title":"Am J RespirCrit Care Med"},{"key":"1331_CR48","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1136\/thx.2004.022590","volume":"59","author":"P Aurora","year":"2004","unstructured":"Aurora P, Gustafsson P, Bush A, Lindblad A, Oliver C, Wallis CE, Stocks J. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax. 2004;59:1068\u201373.","journal-title":"Thorax"},{"key":"1331_CR49","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jcf.2020.05.010","volume":"19","author":"M Shaw","year":"2020","unstructured":"Shaw M, Khan U, Clancy JP, Donaldson SH, Sagel SD, Rowe SM, Ratjen F, PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Changes in LCI in F508del\/F508del patients treated with lumacaftor\/ivacaftor: results from the prospect study. J Cyst Fibros. 2020;19:931\u20133.","journal-title":"J Cyst Fibros"},{"key":"1331_CR50","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1164\/rccm.201802-0243LE","volume":"198","author":"F Ratjen","year":"2018","unstructured":"Ratjen F, Klingel M, Black P, Powers MR, Grasemann H, Solomon M, Rosenfeld M. Changes in lung clearance index in preschool-aged patients with cystic fibrosis treated with ivacaftor (GOAL): Aclinical trial. Am J Respir Crit Care Med. 2018;198:526\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1331_CR51","doi-asserted-by":"publisher","first-page":"e1656","DOI":"10.1002\/mgg3.1656","volume":"9","author":"V Terlizzi","year":"2021","unstructured":"Terlizzi V, Amato F, Castellani C, Ferrari B, Galietta LJV, Castaldo G, Taccetti G. Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Mol Genet Genomic Med. 2021;9:e1656.","journal-title":"Mol Genet Genomic Med"},{"key":"1331_CR52","doi-asserted-by":"publisher","first-page":"1700433","DOI":"10.1183\/13993003.00433-2017","volume":"50","author":"E Oude Engberink","year":"2017","unstructured":"Oude Engberink E, Ratjen F, Davis SD, Retsch-Bogart G, Amin R, Stanojevic S. Inter-test reproducibility of the lung clearance index measured by multiple breath washout. Eur Respir J. 2017;50:1700433.","journal-title":"Eur Respir J"},{"key":"1331_CR53","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000225373","volume":"78","author":"PD Robinson","year":"2009","unstructured":"Robinson PD, Goldman MD, Gustafsson PM. Inert gas washout: theoretical background and clinical utility in respiratory disease. Respiration. 2009;78:339\u201355.","journal-title":"Respiration"},{"key":"1331_CR54","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jcf.2019.02.007","volume":"18","author":"KM Hardaker","year":"2019","unstructured":"Hardaker KM, Panda H, Hulme K, Wong A, Coward E, Cooper P, et al. Abnormal preschool Lung Clearance Index (LCI) reflects clinical status and predicts lower spirometry later in childhood in cystic fibrosis. J Cyst Fibros. 2019;18:721\u20137.","journal-title":"J Cyst Fibros"},{"key":"1331_CR55","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1183\/09031936.00072510","volume":"37","author":"R Amin","year":"2011","unstructured":"Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J. 2011;37:806\u201312.","journal-title":"Eur Respir J"},{"key":"1331_CR56","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jcf.2021.02.004","volume":"20","author":"C Voldby","year":"2021","unstructured":"Voldby C, Green K, Philipsen L, Sandvik RM, Skov M, Buchvald F, et al. Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis. J Cyst Fibros. 2021;20:949\u201356.","journal-title":"J Cyst Fibros"},{"key":"1331_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jcf.2017.07.001","volume":"17","author":"D Hubert","year":"2018","unstructured":"Hubert D, Dehillotte C, Munck A, David V, Baek J, Mely L, et al. Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting. J Cyst Fibros. 2018;17:89\u201395.","journal-title":"J Cyst Fibros"},{"key":"1331_CR58","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jcf.2021.08.014","volume":"21","author":"E Granger","year":"2022","unstructured":"Granger E, Davies G, Keogh RH. Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor? J Cyst Fibros. 2022;21:316\u201322.","journal-title":"J Cyst Fibros"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-022-01331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-022-01331-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-022-01331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T10:08:03Z","timestamp":1659607683000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-022-01331-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1331"],"URL":"https:\/\/doi.org\/10.1186\/s13052-022-01331-5","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"12 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}